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Development of metastases is a multi-step process, and invasion of
surrounding tissues by cancer cells is an initial step. The concerted
action of various matrix metalloproteinases (MMPs) and serine
proteinases such as plasmin and plasminogen activators is
believed to be a key event in this step (Mignatti et al, 1986). We
have shown that tumour-associated trypsin may participate in this
process (Koivunen et al, 1991a; Sorsa et al, 1997). Two variants of
the trypsinogen isoenzymes trypsinogen-1 (cationic) and
trypsinogen-2 (anionic), called tumour-associated trypsinogen-1
and -2, have been shown to occur in ovarian tumour cyst fluid
(Koivunen et al, 1989). Recently, extrapancreatic expression of
trypsinogen has been observed in several human malignancies
such as ovarian (Koivunen et al, 1989; Hirahara et al, 1995) and
gastric cancer (Fujimura et al, 1998) and in cholangiocarcinoma
(Terada et al, 1995). Several tumour cell lines also express
trypsinogen (Koivunen et al, 1991b; Koshikawa et al, 1994). In
human ovarian and gastric cancer, the trypsin expression is associ-
ated with the malignant potential of the tumours (Koivunen et al,
1990; Hirahara et al, 1998; Miyata et al, 1998; Kato et al, 1998). 
In extracellular fluids, the activity of trypsin is controlled by
several inhibitors, e.g. a1-protease inhibitor (API), also called a1-
antitrypsin, and a2-macroglobulin (Ohlsson, 1988). Tumour-asso-
ciated trypsin inhibitor (TATI), which is identical to pancreatic
secretory trypsin inhibitor (PSTI), is thought to prevent intra-
cellular activation of trypsinogens (Stenman et al, 1991). TATI is
expressed together with trypsinogen by several tumours and
cancer cell lines (Stenman et al, 1991). TATI in serum has been
used as a tumour marker for mucinous ovarian cancer and it is a
prognostic factor in stage III epithelial ovarian cancer (Venesmaa
et al, 1998). 
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are believed
to play major roles in tumour invasion by degrading type IV
collagen, the main component of basement membranes (Liotta et
al, 1980; Bernhard et al, 1994). It has been suggested that MMP-2
expression is a phenotypic characteristic of malignant epithelial
ovarian tumours (Autio-Harmainen et al, 1993) and a potentially
useful prognostic marker (Garzetti et al, 1995). Recently, Furuya
et al (2000) showed that MMP-2 and MMP-9 occured at higher
concentrations in cyst fluids from malignant than from benign
mucinous ovarian tumours. 
MMPs are frequently over-expressed in tumours (Levy et al,
1991; Davies et al, 1993) but this does not automatically imply
increased proteolytic activity, because most MMPs are
secreted as inactive zymogens requiring proteolytic removal of the
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et al, 1987). The urokinase type plasminogen activator (uPA) –
plasmin system (Mazzieri et al, 1997) and membrane type MMP-1
(MT1-MMP, MMP-14) (Sato et al, 1994; Tokuraku et al, 1995)
have been suggested to represent physiological mechanisms for
the control of MMP-2 and MMP-9 activity. Recent studies have
shown that human trypsin-2 is more potent than plasmin and other
serine proteinases in activating several MMPs, including MMP-2
and MMP-9 (Sorsa et al, 1997), and that downregulation of
trypsin-2 expression and activity in colon cancer cells is associated
with decreased proMMP-9 activation (Lukkonen et al, 2000). 
In the present study we investigated the involvement of trypsin
in the activation of MMP-2 and MMP-9 in vivo by studying
whether the concentrations of trypsins, trypsin-API-complexes,
and TATI are associated with activation of proMMP-2 and
proMMP-9 in ovarian tumour cyst fluid. Furthermore, we studied
the immunohistochemical expression and localization of
trypsinogen-2, TATI, MMP-2, and MMP-9 in ovarian tumours. 
MATERIALS AND METHODS 
Clinical specimens 
Cyst fluid samples (n = 61) were obtained from 58 patients (age
range 13–79 years) undergoing surgery for removal of the tumour
during 1986–1998 at Helsinki University Central Hospital. Of the
tumours, 41 were benign and 20 malignant. The tumours were
classified histologically into three main groups: mucinous and
serous cystadenomas and their malignant counterparts, and other
types of ovarian tumours. The benign tumours included 15 muci-
nous and 6 serous cystadenomas, and 20 other types of ovarian
tumours (1 fibroma, 3 benign ovarian teratomas, and 16 non-
neoplastic cysts). The malignant tumours included seven muci-
nous and nine serous cystadenocarcinomas, two mesonephroid
adenocarcinomas, one mixed type carcinoma and one yolk sac
tumour. The volume of cyst fluid ranged from 20 to 3000 ml. The
fluids were centrifuged at 10 000 rpm for 10 min and aliquots were
stored at –20˚C until analysed. 
Ovarian cancer tissues were obtained from 20 patients (age
range 37–84) undergoing surgery for removal of the tumour during
1990–1995 at Helsinki University Central Hospital. Samples
included 10 mucinous and 10 serious ovarian cystadenocarci-
nomas. Tumour stage and grade were classified according to
International Federation of Gynecology and Obstetrics (FIGO)
(Benedet et al, 2000). Eight tumours were well-differentiated
(Grade 1), seven moderately differentiated (Grade 2), and 3 poorly
differentiated. For two tumours grade was not available. Nine
cases represented Stage I, three Stage II, six Stage III, and two
stage IV ovarian cystadenocarcinoma. This study was carried out
with approval of the ethical committee of the Department of
Obstetrics and Gynecology, Helsinki University Central Hospital. 
Antibodies 
Monoclonal antibodies against human trypsinogen-2 (Itkonen 
et al, 1990) and TATI (Osman et al, 1993), and a polyclonal 
antibody against trypsinogen (Koivunen et al, 1989) were
prepared as described. Polyclonal antibodies against MMP-2
(Turpeenniemi-Hujanen et al, 1992; Väisänen et al, 1998) and
MMP-9 (Kjeldsen et al, 1993) were kindly provided by Dr Taina
Turpeenniemi-Hujanen and Dr Lars Kjeldsen, respectively. The
same polyclonal antibodies against MMP-2 and MMP-9 were used
in Western blotting and immunohistochemistry. 
Western blotting 
For Western blot analysis, 15 ml of cyst fluids (diluted 1:10 for
MMP-2 and 1:5 for MMP-9 Western blotting) were mixed with a
sample buffer containing 20% (v/v) glycerol, 6% (w/v) sodium
dodecyl sulfate, and 0.4% (w/v) promophenol blue in 0.1 M tris-
phosphate buffer, pH 6.8. The samples were run on 7.5% SDS-
polyacrylamide gel electrophoresis under non-reducing conditions
(Laemmli, 1970) and transferred to ProtranP Nitrocellulose
Transfer Membrane (Schleicher & Schüll GmbH, Dassel,
Germany) electrophoretically at 40 mA for 1 h in 25 mM Tris-
HCl, pH 8.3 containing 192 mM glycine and 20% methanol.
Nonspecific binding was blocked with 5% non-fat dry milk in
phosphate buffered saline (PBS) (pH 7.2) for 90 min at 37 ˚C. The
blots were incubated with a 1:500 dilution of polyclonal antibodies
against either human trypsinogen, MMP-2, or MMP-9, or with
nonimmune control serum (DAKO A/S, Glostrup, Denmark) for 3
h at 37 ˚C followed by peroxidase-conjugated second antibodies
(1:200 dilution, DAKO A/S) for 1 h at 22 ˚C. After washing, the
blots were developed with a solution of 60 mg/ml diaminobenzi-
dine tetrahydrocholoride in 50 mM Tris-HCl, pH 8.0, and 0.003%
H2O2 (Sorsa et al, 1997). 
Gelatin zymography 
For analysis of MMP-2 and MMP-9 by zymography, cyst fluids 
(5 ml, diluted 1:25) were mixed with the same sample buffer as 
in Western blotting and run on 1.5 mm thick 7.5–10% SDS-
polyacrylamide gels impregnated with 1 mg/ml gelatin (Sigma).
After electrophoresis at 4 ˚C, the gels were washed for 30 min at
room temperature (RT) in 50 mM Tris-HCl buffer, pH 7.8,
containing 2.5% Tween-80, and 0.02% (w/v) NaN3 for 30 min in
the same buffer containing 1 mM CaCl2 and 1 mM ZnCl2. After
washing, the gels were incubated in 50 mM Tris-HCl, pH 7.8,
containing 150 mM NaCl, 1 mM CaCl2, 1 mM ZnCl2, and 0.02%
NaN3 for 48 h at 37 ˚C and stained with Coomassie Brilliant Blue.
The total MMP content and the proportions of proforms and active
forms of MMP-2 and MMP-9 were estimated with the Bio-Rad
Model GS-700 Imaging Densitometer using the Molecular
Analyst TM/PC program (Lukkonen et al, 2000). 
Immunofluorometric assays 
Immunofluorometric assays for trypsinogen-1 and trypsinogen-2
(Itkonen et al, 1990), trypsin-1-API complex (Hedström et al,
1999), trypsin-2-API complex (Hedström et al, 1994), and TATI
(Osman et al, 1993) were performed as earlier described. The
detection limit was 0.1 mg/l for trypsinogen-1, 0.3 mg/l for
trypsinogen-2, 0.4 m/l for trypsin-1-API, 0.05 mg/l for trypsin-2-
API, and 0.2 mg/l for TATI. The inter-and intra-assay coefficients
of variation (CV) were 10–15% for trypsinogen-1, 10–12% for
trypsinogen-2, 7–16% for trypsin-1-API, 4.8–6.4% and 7.3–10.4%
for trypsin-2-API, and 3.0–8.6% and 13–14% for TATI (Itkonen 
et al, 1990; Hedström et al, 1999; Hedström et al, 1994; Osman 
et al, 1993). 
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Formalin-fixed, paraffin embedded tissue sections (4 mm) were
deparaffinized in xylene and rehydrated by sequential incubation
in ethanol-water solutions. The deparaffinized tissue sections
were pretreated with 0.4% pepsin (Sigma), pH 1.8 for 10 min at
37˚C (MMP-2 and MMP-9), with 0.5% trypsin (Difco
Laboratories, Detroit, MI, USA), pH 7.0 for 30 min at 37 ˚C
(TATI), or with microwave heat in 10 mM sodium citrate buffer,
pH 6.0 for 4 ´ 5 min (700 W) (trypsinogen-2). All sections were
incubated first in 0.5% hydrogen peroxide in methanol for 15 min
to quench endogenous peroxidase activity and then with non-
immune mouse or rabbit serum diluted 1:67 for 15 min. The
primary antibodies against trypsinogen-2 (diluted 1:1000), TATI
(diluted 1:5000), MMP-2 (diluted 1:8000), and MMP-9 (diluted
1:1000) were added and the sections were incubated overnight 
at 4˚C. Bound antibodies were visualized by the avidin–
biotin complex immunoperoxidase technique (ABC) (Elite ABC
Kit, Vectastain, Vector Laboratories, Burlingame, CA, USA)
following the manufacturer’s instructions. The sections were
incubated with the biotinylated second layer antibody and the
peroxidase-labelled avidin-biotin complex for 30 min each. All
dilutions were made in PBS and all incubations were carried out
in humid chambers at RT. The peroxidase staining was visualized
with a solution of 0.2 mg/ml 3-amino-9-ethyl-carbazole (Sigma,
A-5754) in 0.05 M acetate buffer, pH 5.0, and 0.03% H2O2 for 15
min at RT. The sections were counterstained with Mayer’s
hemalum solution (Merck). For each tissue section, a negative
control was stained by replacing the monoclonal and polyclonal
primary antibodies with non-immune mouse or rabbit IgGs,
respectively. Sections of specimens known to be positive for
trypsinogen-2, TATI, MMP-2, and MMP-9 were used as positive
controls. The effect of different pre-treatments (microwave oven
treatment, incubation in 0.5% trypsin, 0.4% pepsin, or PBS) was
tested for each antibody and methods resulting in optimal staining
reactions were used. 
Statistical analysis 
The Mann–Whitney test was performed to estimate the statistical
significance of differences. All P values resulted from the use of
two-sided tests, and P values ≤ 0.05 were considered significant.
RESULTS 
Concentrations of trypsinogen-1, trypsinogen-2,
trypsin-1-API, trypsin-2-API, and TATI 
The concentrations of trypsinogen-1, trypsinogen-2, trypsin-1-
API, and trypsin-2-API were higher in malignant than in benign
cyst fluids (P < 0.02) (Figure 1) whereas there was no significant
difference in TATI concentrations. In mucinous cyst fluids, the
TATI concentrations were significantly higher in benign than in
malignant fluids (P < 0.04). In serous cyst fluids trypsinogen-2,
trypsin-2-API, and trypsin-1-API concentrations were higher in
malignant than in benign fluids (P < 0.02, P < 0.05, and P <0.03,
respectively) whereas there was no difference in trypsinogen-1 and
TATI concentrations. The trypsinogen-2, trypsin-2-API, and TATI
concentrations were higher in mucinous than in serous fluids 
both in malignant and benign cyst types (P ≤ 0.01 and P = 0.03,
respectively) (Figure 2), while there were no differences in
trypsinogen-1 and trypsin-1-API concentrations. The molar ratio
of trypsinogen-1 and -2 to TATI was higher in serous than in muci-
nous cyst fluids (P < 0.001). 
Activation of pro-MMP-2 and pro-MMP-9 
In Western blotting and zymography, MMP-2 and MMP-9
migrated as 62 & 72 and 77 & 92 kDa bands, respectively (Figure
4A, B, D). Western blotting revealed additional 30–50 kDa frag-
ments of both MMP-2 and MMP-9 (Figure 4A and B). In Western
blotting and zymography, trypsinogen migrated as 25 & 28 kDa
bands (Figure 4C and D). The MMP-9 content determined by
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Figure 1 Box plot of the concentrations of (A) trypsinogen-1 and trypsin-1-API and (B) trypsinogen-2 and trypsin-2-API in cyst fluids of malignant and benign
ovarian tumours. The box denotes the 25th, 50th, and 75th percentiles while the whiskers represent the 10th and 90th percentiles. Values outside these limits
are indicated by circles. The number of samples analysed is shown in parenthesiszymography was significantly higher in malignant than in benign
cyst fluids (2-fold, P = 0.03) whereas there was no difference in
MMP-2 content. The ratio of active and inactive forms of MMP-2
and MMP-9 was analysed by zymography and compared with the
concentrations of trypsinogens, trypsin-API complexes, and TATI.
The proportion of active MMP-9 was significantly greater in cyst
fluids with high trypsinogen-2 concentration than in those with
low trypsinogen-2 concentration (< 87 mg/1) (P = 0.05) (Figure
4A). The proportion of active MMP-9 was also greater in cyst
fluids with trypsin-1-API and trypsin-2-API concentrations higher
than their median concentrations (12 and 42 mg/1, respectively) (P
= 0.4 and 0.1, respectively). The differences were statistically
significant at cut-off levels of 30 mg/1 (trypsin-1-API) and 100
mg/1 (trypsin-2-API) (P = 0.003 and 0.03, respectively).
Contrary to MMP-9, the activation of MMP-2 was inversely
associated with trypsinogen-1, trypsinogen-2, trypsin-2-API, and
TATI concentrations. The proportion of active form of MMP-2
was smaller when trypsinogen-1 and trypsin-2-API concentrations
were higher than their median concentrations (20 and 42 mg/l,
respectively) (P = 0.02). Similarly, less active MMP-2 occurred in
cyst fluids with trypsinogen-2 and TATI concentrations higher
than their median concentrations (87 and 25 mg/l, respectively) 
(P = 0.1 and 0.2, respectively). The results were statistically
significant when cut-off concentrations 50 mg/l (trypsinogen-2)
and 1000 mg/l (TATI) were used (P = 0.01 and 0.04, respectively)
(Figure 4B). 
Localization of trypsinogen and MMP immunoreactivity
in ovarian cancer tissues 
By immunohistochemistry, trypsinogen-2 was found in the epithe-
lium of 8 of 10 (80%) mucinous and in 4 of 10 (40%) serous
cystadenocarcinomas. TATI was detected in the epithelium of 9 of
10 (90%) mucinous and in 1 of 10 (10%) serous cystadenocarci-
nomas (Table 1, Figure 5). Of mucinous cystadenocarcinomas 9 of
10 (90%) showed MMP-2 immunoreactivity in stromal cells, 5 of
10 (50%) in epithelium, and all (100%) in vascular endothelium.
Of serous cystadenocarcinomas 8 of 10 (80%) showed MMP-2
immunoreactivity in stromal cells, 4 of 10 (40%) in epithelium,
and 6 of 10 (60%) in vascular endothelium. MMP-9-positive
neutrophils and monocyte-macrophage-like cells were detected in
stromal and epithelial areas in 8 of 10 (80%) mucinous and 7 of 10
(70%) serous cystadenocarcinomas (Table 1, Figure 6). 
DISCUSSION 
Tumour-associated trypsinogens and TATI are produced by
various human cancers (Koivunen et al, 1989; Hirahara et al,
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Figure 2 Concentrations of trypsinogen-2, trypsin-2-API, and TATI in mucinous and serous cyst fluids of (A) benign and (B) malignant ovarian tumours. The
symbols are as in Figure 1
Table 1 Summary of trypsinogen-2, TATI, MMP-2, and MMP-9 immunostaining of ovarian cancer specimens
Trypsinogen-2 (0/1/2–3) TATI (0/1/2–3) MMP-2 (0/1/2–3) MMP-9 (+/–) 
Histology n (EP) (EP) (S) (EP) (EN) (M/N) 
Mucinous 10 2/2/6 1/1/8 1/5/4 5/3/2 0/7/3 8/2 
Serous 10 6/2/2 9/0/1 2/5/3 6/2/2 4/2/4 7/3 
0 = immunoreactivity absent; 1 = weak immunoreactivity; 2–3 = moderate or strong immunoreactivity; +/2=
immunoreactive cells detected/not detected. EP = epithelium; S = stroma; EN = endothelium; M/N = macrophages
and/or neutrophils; TATI = tumour-associated trypsin inhibitor; MMP = matrix metalloproteinase. Trypsin and gelatinases in ovarian tumour cyst fluids 1367
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Figure 3 Western blot analysis of cyst fluids from two patients with benign ovarian cysts using a polyclonal antibody against MMP-9 (A) and a polyclonal
antibody against MMP-2 (B). Panel (C) shows Western blot analysis of cyst fluid from a patient with mucinous ovarian tumour using a polyclonal antibody
against trypsinogen. Panel (D) shows zymography of cyst fluids from two patients with mucinous ovarian tumour
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Figure 4 (A) Ratio of active MMP-9 to proMMP-9 in ovarian tumour cyst fluids in relation to trypsinogen-2, trypsin-1-API, and trypsin-2-API concentrations.
(B) Ratio of active MMP-2 to proMMP-2 in ovarian tumour cyst fluids with respect to trypsinogen-1, trypsinogen-2, trypsin-2-API, and TATI concentration. The
symbols are as in Figure 11995; Terada et al, 1995) and tumour cell lines (Koivunen et al,
1991b; Koshikawa et al, 1994). The main tumour-associated
isoenzyme, trypsin-2, activates pro-urokinase-type plasminogen
activator (pro-uPA) (Koivunen et al, 1989) and in vitro it is the
most efficient activator of the 92 kDa gelatinase B (MMP-9)
known thus far (Sorsa et al, 1997). Therefore, trypsin may partici-
pate in cancer cell-mediated proteolysis by directly degrading the
extracellular matrix or by activating other proteinases (Koivunen
et al, 1991a). 
The expression of MMP-2 and MMP-9 correlates with the inva-
sive and metastatic potential of various tumours (Höyhtyä et al,
1990; Juarez et al, 1993; Bernhard et al, 1994). The zymogen
forms of MMP-2 and MMP-9 can be activated by several
proteinases in vitro and it has been suggested that cell surface-
bound MMP-14 plays an important role in the activation of 
MMP-2 (Sato et al, 1994) and plasmin in the activation of MMP-9
(Mazzieri et al, 1997). Most studies concerning the activation of
MMPs have been performed in vitro, and only a few studies have
provided evidence of activation in vivo. A correlation between
MMP-14 expression and activation of MMP-2 has been observed
in cancer tissues (Tokuraku et al, 1995) suggesting that MMP-14 is
a physiological activator of MMP-2. In an in vivo model of acute
lung injury neutrophil elastase was found to be a potential physio-
logical activator of MMP-9 (Ferry et al, 1997). 
The results of the present study show that high concentrations of
trypsinogens and trypsin-API complexes in cyst fluids of ovarian
tumours correlate with increased MMP-9 and decreased MMP-2
activation. This suggests that trypsin-1 and trypsin-2 may be
involved in the activation of MMP-9 but not MMP-2 in vivo.
Although human trypsin-2 reportedly activates MMP-2 in vitro it
has been observed that MMP-2 is further fragmented in its C-
terminal region during a prolonged incubation with trypsin-2
(Sorsa et al, 1997). It is possible that trypsin, a very efficient
proteinase, may inactivate MMP-2 or its activator MMP-14 when
occurring at high concentrations. Several other factors, e.g. other
MMPs, the uPA-plasmin system, and tissue inhibitors of matrix
metalloproteinases (TIMPs) also affect the activity of MMP-2 and
MMP-9. TIMP-1 which is present in cyst fluids at high concentra-
tions (Furuya et al, 2000) can reduce but not abolish the activation
of MMP-9 by trypsin-2 (Sorsa et al, 1997). 
In line with the findings of Furuya et al (2000), the total MMP-
9 content was significantly higher in malignant than in benign cyst
fluids whereas there was no difference in the total MMP-2 content.
Consistent with the study of Koivunen et al (1990), we found that
the concentrations of trypsinogen-1 and trypsinogen-2, but not
those of TATI were significantly higher in malignant than in
benign cyst fluids. In addition, the concentrations of trypsin-API
complexes, which reflect the proportion of active trypsin, were
significantly higher in malignant than in benign fluids.
Interestingly, the molar ratio of trypsinogen to TATI was signifi-
cantly higher in serous than in mucinous cyst fluids. This may 
be related to the poorer prognosis of serous than mucinous 
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Figure 5 Immunohistochemical expression of trypsinogen-2 in a grade 1 mucinous cystadenocarcinoma (A, B), trypsinogen-2 in a grade 1 serous
cystadenocarcinoma (C, D), and tumour-associated trypsin inhibitor in a grade 2 mucinous cystadenocarcinoma (F). Panel (E) shows a negative control. Scale
bars, 50 mm (A, C, E, F) and 12.5 mm (B, D)ovarian carcinomas at an early stage of the disease (Vergote et al,
1993). 
By immunohistochemistry, we detected trypsinogen-2 and TATI
in the secretory epithelium of ovarian carcinomas as has been
earlier described (Ueda et al, 1989; Hirahara et al, 1995).
Trypsinogen-2 and TATI immunoreactivity was detected more
frequently in mucinous than in serous tumours and in agreement
with this, the trypsinogen and TATI concentrations were found to
be significantly higher in mucinous than in serous cyst fluids. In
ovarian carcinomas, MMP-2 mRNA expression has been detected
mainly in stromal fibroblasts and endothelial cells but only rarely
in epithelial cells (Autio-Harmainen et al, 1993; Afzal et al, 1998;
Naylor et al, 1994) whereas immunoreactive MMP-2 has
frequently been detected in the cytoplasm and at the surface of
epithelial tumor cells (Autio-Harmainen et al, 1993; Afzal et al,
1996; De Nictolis et al, 1996; Höyhtyä et al, 1994). However,
several cultured ovarian carcinoma cells produce MMP-2 and
MMP-9 (Moser et al, 1994; Fishman et al, 1997; Boyd and
Balkwill, 1999; Westerlund et al, 1997) and a cell-cell interaction
in a coculture of fibroblasts and carcinoma cells stimulates MMP-
2 expression and in vitro cancer cell invasion (Boyd and Blakwill,
1999; Westerlund et al, 1997). In agreement with earlier studies
(Autio-Harmainen et al, 1993; Afzal et al, 1996; De Nictolis et al,
1996; Höyhtyä et al, 1994) we found by immunohistochemistry
that MMP-2 localized to the vascular endothelial, epithelial, and
stromal cells. Furthermore, in line with several studies suggesting
stromal macrophages and tumour-infiltrating neutrophils as major
sources of MMP-9 in invasive cancers, e.g. in colon (Nielsen et al,
1996; Pyke et al, 1993), breast (Davies et al, 1993a), and bladder
cancer (Davies et al, 1993b) and in ovarian carcinoma (Naylor 
et al, 1994), we detected MMP-9 immunoreactivity in neutrophils
and monocyte-macrophage-like cells both in stromal and epithelial
areas. This is in contrast to the findings of Huang et al (2000), who
recently demonstrated MMP-9 mRNA and protein both in stromal
and neoplastic cells of ovarian carcinomas (Huang et al, 2000).
The immunohistochemical findings support the notion that stromal
cells, inflammatory cells, and cancer cells cooperatively produce,
induce, and activate tissue-destructive serine proteinases and
MMPs that facilitate tumour invasion and metastatic spread (Pyke
et al, 1993). 
In conclusion, high levels of trypsin-1 and -2 in ovarian tumour
cyst fluids were associated with increased activation of MMP-9
but decreased activation of MMP-2. These findings suggest that
trypsin may represent a physiological regulator of the matrix
metalloproteinase cascade involved in local invasion and
metastatic spread of ovarian tumours. 
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